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Baker and Alderson emphasise elements of the available data to support the decision made by 
NICE to withdraw antibiotic prophylaxis for patients at risk of infective endocarditis in the 
UK. Differing interpretations of best practice in the context of limited data are the essence of 
the ‘uncertainty’ which underlies the BMJ’s series and are to be welcomed. As outlined 
explicitly in our Uncertainties article,(1) Baker and Alderson reiterate that dental procedures 
account for a minority of cases, that the absolute risk of infective endocarditis after a given 
procedure is low, and that there are potential risks associated with antibiotic prophylaxis 
(although contemporary UK data suggest that there has never been a death associated with 
amoxicillin antibiotic prophylaxis).(2) We acknowledge these caveats.  
However, given the evidence of possible benefit and very low risk of harm, we believe that 
decisions concerning the use of antibiotic prophylaxis should be devolved to individual 
patients and not taken at national level. This approach, that is supported by European and 
American guidelines, allows those at highest risk to make decisions regarding their care with 
support from general practitioners, cardiologists and dentists.  
We are in complete agreement that the rising incidence of infective endocarditis observed in 
multiple countries is a cause for concern, and that research funding is required to understand 
this. Furthermore, research needs to not only clarify the role of antibiotic prophylaxis for 
invasive dentistry, but also investigate other novel preventative strategies. 
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